| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Cistanoside F targets NADPH-oxidase, an enzyme complex that generates superoxide anion radicals. By inhibiting NADPH-oxidase activity, it reduces the production of reactive oxygen species (ROS), thereby exerting its antioxidant effects. It may also interact with pathways involved in vascular smooth muscle contraction, contributing to its vasorelaxant properties.
|
|---|---|
| ln Vitro |
Cistanoside F demonstrates strong free radical scavenging activity on DPPH radicals and xanthine/xanthine oxidase (XOD)-generated superoxide anion radicals (O₂⁻). The compound (10-100 μM) significantly inhibits norepinephrine-induced contractions in isolated rat aortic strips in a time- and concentration-dependent manner. Unlike nifedipine, it does not affect high K⁺-induced contractions, suggesting a specific mechanism of action.
|
| ln Vivo |
Cistanoside F shows vasorelaxant activity in isolated rat aortic strip models. In vivo formulation studies have been conducted, with the compound soluble in a vehicle of 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline at 3.3 mg/mL. Its antioxidant properties suggest potential for protecting against oxidative stress-related conditions in vivo.
|
| Enzyme Assay |
In vitro enzyme inhibition assays for Cistanoside F typically involve measuring its free radical scavenging activity. The DPPH radical scavenging assay is performed by incubating the compound with DPPH solution and measuring the decrease in absorbance at 517 nm. The xanthine/xanthine oxidase (XOD) assay measures the compound's ability to scavenge superoxide anion radicals generated by the XOD enzyme system. These cell-free assays quantify the compound's antioxidant capacity.
|
| Cell Assay |
Cellular assays for Cistanoside F are performed using vascular smooth muscle cells or aortic strips. Isolated rat aortic strips are pre-contracted with norepinephrine, and the relaxation effect of Cistanoside F (10-100 μM) is measured. The compound's lack of effect on high K⁺-induced contractions is assessed in the same tissue model. These assays characterize the compound's vasorelaxant and antioxidant activities at the cellular level.
|
| Animal Protocol |
In vivo animal experiments for Cistanoside F are not extensively documented. Based on formulation data, the compound can be administered via intraperitoneal or oral routes using a vehicle of 10% DMSO, 40% PEG300, 5% Tween-80, and 45% saline. Typical studies would involve administration to rodent models to assess antioxidant or vasorelaxant effects, with endpoints including blood pressure, oxidative stress markers, and tissue histology.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Cistanoside F have not been systematically characterized. The compound has a molecular weight of 488.44 and molecular formula C₂₁H₂₈O₁₃. It is soluble in DMSO (80 mg/mL), pyridine, methanol, and ethanol. It should be stored as a powder at -20°C for up to 3 years or at 4°C for up to 2 years. In vivo formulation is soluble at 3.3 mg/mL.
|
| Toxicity/Toxicokinetics |
Toxicological data for Cistanoside F are not extensively reported. As a natural product research compound, its safety profile has not been formally evaluated in comprehensive preclinical toxicology studies. It is intended for research purposes only and is not approved for human therapeutic use. Standard laboratory safety precautions should be followed when handling this compound.
|
| References | |
| Additional Infomation |
Cistanoside F has been reported to be found in Acanthus ilicifolius, Rehmannia glutinosa, and other organisms with available data.
Cistanoside F is a natural phenylethanol glycoside with CAS number 97411-47-7, molecular formula C₂₁H₂₈O₁₃, and molecular weight 488.44. It is isolated from Cistanche deserticola and Cistanche tubulosa, plants used in traditional Chinese medicine. The compound exhibits antioxidant, vasorelaxant, and potential neuroprotective effects. It is supplied with purity ≥98% and is for research use only. |
| Molecular Formula |
C21H28O13
|
|---|---|
| Molecular Weight |
488.4392
|
| Exact Mass |
488.152
|
| CAS # |
97411-47-7
|
| PubChem CID |
101688189
|
| Appearance |
Off-white to yellow solid powder
|
| Density |
1.6±0.1 g/cm3
|
| Boiling Point |
880.7±65.0 °C at 760 mmHg
|
| Flash Point |
302.8±27.8 °C
|
| Vapour Pressure |
0.0±0.3 mmHg at 25°C
|
| Index of Refraction |
1.654
|
| LogP |
1.5
|
| Hydrogen Bond Donor Count |
8
|
| Hydrogen Bond Acceptor Count |
13
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
34
|
| Complexity |
688
|
| Defined Atom Stereocenter Count |
9
|
| SMILES |
C[C@@H]1[C@H]([C@@H]([C@@H]([C@H](O1)O[C@@H]2[C@H]([C@@H](O[C@@H]([C@H]2OC(=O)/C=C/C3=CC(=C(C=C3)O)O)CO)O)O)O)O)O
|
| InChi Key |
IDVRYIVYDAOHSS-CRADLMAESA-N
|
| InChi Code |
InChI=1S/C21H28O13/c1-8-14(26)15(27)16(28)21(31-8)34-19-17(29)20(30)32-12(7-22)18(19)33-13(25)5-3-9-2-4-10(23)11(24)6-9/h2-6,8,12,14-24,26-30H,7H2,1H3/b5-3+/t8-,12-,14-,15+,16+,17-,18-,19-,20-,21-/m1/s1
|
| Chemical Name |
[(2R,3R,4R,5R,6R)-5,6-dihydroxy-2-(hydroxymethyl)-4-[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl] (E)-3-(3,4-dihydroxyphenyl)prop-2-enoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~204.73 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.12 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.12 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (5.12 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0473 mL | 10.2367 mL | 20.4733 mL | |
| 5 mM | 0.4095 mL | 2.0473 mL | 4.0947 mL | |
| 10 mM | 0.2047 mL | 1.0237 mL | 2.0473 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
